Back to News
Feb 9, 2026 8:30 AM

QuantX Biosciences Closes Oversubscribed $85M Series B Financing

PRINCETON, N.J. and SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- QuantX Biosciences, Inc., a computationally driven drug discovery and development company using advanced modeling and high-performance computing to rapidly design and optimize oral small molecule therapeutics, announced today the close of an oversubscribed $85 million Series B financing co-led by LAV and Sanofi Ventures. Additional investors included Hongshan, and existing investors.

The proceeds from this financing will be used to support the clinical development of its best-in-class STAT6 oral small molecule inhibitor and IL-17 oral small molecule inhibitor, in addition to continued discovery efforts for oral therapies in immunology and inflammation.

"This fundraising is a watershed moment for QuantX as we continue to refine our strong discovery engine, add to our robust pipeline, and advance multiple programs towards ...